Skip to main content

Advertisement

Erratum to: Fish oil: what the prescriber needs to know

The original article was published in Arthritis Research & Therapy 2005 8:202

It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005.

All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'.

The second paragraph should read:

The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).

The last sentence of the third paragraph should read:

Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2).

Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.

References

  1. 1.

    Cleland LG, James MJ, Proudman SM: Fish oil: what the prescriber needs to know. Arthritis Research & Therapy. 2006, 8: 202-10.1186/ar1876.

Download references

Author information

Correspondence to Michael J James.

Additional information

The online version of the original article can be found at 10.1186/ar1876

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cleland, L.G., James, M.J. & Proudman, S.M. Erratum to: Fish oil: what the prescriber needs to know. Arthritis Res Ther 8, 402 (2006) doi:10.1186/ar1981

Download citation